Bellemin Jean-Marc 4
4 · IOVANCE BIOTHERAPEUTICS, INC. · Filed Sep 5, 2024
Insider Transaction Report
Form 4
Bellemin Jean-Marc
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-09-03+23,438→ 41,239 total - Exercise/Conversion
Restricted Stock Units
2024-09-03−23,438→ 23,437 total→ Common Stock (23,438 underlying) - Tax Payment
Common Stock
2024-09-03$10.85/sh−11,891$129,017→ 29,348 total
Footnotes (7)
- [F1]Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
- [F2]Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.
- [F3]Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
- [F4]Represents common stock remaining after deducting the common stock withheld for taxes.
- [F5]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F6]The remaining RSUs will vest on the one-year anniversary of the initial grant date, as provided in footnote 7.
- [F7]Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.